Advanced Malignancies Clinical Trials

A listing of Advanced Malignancies medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 108 clinical trials
A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer

In this study researchers want to gather relevant information regarding the safety of BAY2416964 and how well the drug works in participants with a type of solid tumors that cannot be cured by currently available drugs. Researchers want to find the highest dose of BAY2416964 that participants could take without …

  • 2 views
  • 13 Jun, 2021
  • 20 locations
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in participants with multiple types of advanced cancer (unresectable and/or metastatic) that: 1) have

  • 135 views
  • 16 Jun, 2021
  • 147 locations
BI-1808 as a Single Agent and With Pembrolizumab in Treatment of Advanced Malignancies

advanced malignancies, whose disease has progressed after standard therapy. For the purpose of this study, subjects with advanced malignancies includes subjects with advanced solid tumors (where

  • 0 views
  • 16 Jun, 2021
  • 8 locations
A First in Human Study of BAY2701439 to Look at Safety How the Body Absorbs Distributes and Excretes the Drug and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein

In this study, researchers want to learn about the safety of drug BAY2701439 and how well the drug works in patients with advanced cancer that has the protein HER2 (Human Epidermal growth factor

  • 0 views
  • 05 Jun, 2021
  • 6 locations
Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With mCRPC

bone-damaging effects. There is an unmet medical need to develop steroid-free taxane regimens for patients with advanced cancer to avoid the need for steroid administration pre and post infusion

  • 0 views
  • 15 Jun, 2021
  • 3 locations
  • 0 views
  • 05 Jun, 2021
  • 8 locations
Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

This BVD-523-ABC study builds on the safety and clinical activity experience of previous studies that have evaluated ulixertinib as a novel targeted cancer treatment in cohorts of patients with specific genetic alterations and tumor histologies that result in aberrant MAPK pathway signaling. Early clinical data have demonstrated anti-tumor activity with …

  • 0 views
  • 04 Jun, 2021
  • 14 locations
Study of DCC-3014 in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor

This is a multicenter, open-label Phase 1/2 study of DCC-3014 in patients with malignant solid tumors and tenosynovial giant cell tumor (TGCT). There will be 2 distinct parts in this study: Dose Escalation (Phase 1) and Expansion (Phase 2). Phase 1 will enroll both malignant solid tumor and TGCT patients. …

measurable disease
solid tumor
solid neoplasm
  • 104 views
  • 17 Jun, 2021
  • 24 locations
BI 894999 First in Human Dose Finding Study in Advanced Malignancies

This study is open to adults with different types of advanced cancer (solid tumours). The study is also open to patients with diffuse large B-cell lymphoma in whom previous treatment was not

tyrosine
taxane
bevacizumab
sarcoma
treatment regimen
  • 0 views
  • 15 Jun, 2021
  • 33 locations
Safety Study of SAR442720 in Combination With Pembrolizumab in Patients With Advanced Malignancies

Primary Objective: To characterize the safety and tolerability of SAR442720 in combination with pembrolizumab in patients with advanced solid tumors including NSCLC who progressed on anti-PD-1/PD L1 containing therapy and advanced colorectal cancer (CRC) after progression to all standard of care (SOC) therapy. To define the MTD and RP2D for …

BRAF
KRAS
pembrolizumab
measurable disease
cancer
  • 0 views
  • 10 Jun, 2021
  • 10 locations